| CTNT 0.0315 -21.25% | BURU 0.3305 17.57% | MEHA 0.1147 -11.09% | MWYN 0.681 19.68% | PAPL 0.8619 43.55% | NOK 10.405 5.53% | TSLL 12.395 -4.14% | QS 8.4801 16.01% | SOXS 15.69 -6.61% | YCBD 1.12 20.43% | PMEC 0.6055 -13.66% | CGC 1.46 5.80% | SMR 13.67 0.74% | AKAN 11.94 16.94% | TSLA 379.36 -2.10% | INTC 68.205 4.50% | TLRY 8.11 3.05% | SMCI 27.37 -6.20% | SOXL 112.74 6.72% | AAL 11.98 4.17% | MSOS 5.035 -1.47% | TQQQ 60.05 -0.27% | AIXI 1.189 32.88% | BYND 1.055 -4.09% | OKLL 14.22 19.10% | HIMS 29.84 2.88% | NVTS 19.31 4.55% | APLD 36.165 11.52% | NOWL 3.92 -30.00% | NVDA 202.8799 0.19% | SQQQ 54.905 0.32% | OKLO 79.41 9.67% | PLUG 3.26 2.19% | TZA 5.01 -0.60% | POET 12.19 -4.54% | CMCSA 31.35 6.74% | ALP 0.1931 -16.04% | FFAI 0.387 -8.55% | ONDS 10.87 -1.72% | SST 2.86 2.14% | NFLX 93.73 0.53% | IREN 49.46 2.21% | STM 49.41 10.14% | MBLY 8.95 13.29% | GPUS 0.159 -7.29% | FCHL 0.2092 -12.65% | TRT 11.6001 40.44% | ELAB 3.03 -2.57% | SCO 7.38 -2.12% | MSFT 420.97 -2.76%

Truist Raises Veeva Systems Price Target But Keeps Hold Rating Ahead Of Q2 Results

Truist Securities raised its price target on Veeva Systems Inc. (NYSE:VEEV) to $268 from $230 while maintaining a Hold rating, ahead of the company’s fiscal second-quarter results scheduled for August 27.

The brokerage said it expects results to come in broadly in line or slightly better, supported by positive commentary from peers DOCS and IQV on end-market demand and spending in pharma tech and analytics.

Truist noted that Veeva shares have risen around 20% since the fiscal first-quarter report, compared with an 8% gain in the S&P 500, suggesting investor expectations already price in a “beat and raise” outcome.

The analysts added that while the mix of a Q2 beat could be important, they expect management to maintain its view for the second half, guiding largely in line with the Q2 performance rather than providing a significant upward revision.

Published on: August 21, 2025